Gateway Health Alliances, Inc. (GHA) based in Fairfield, CA, has identified new indigenous ingredients for the food and beverage, functional food, and dietary supplement markets sourced from West Africa.
Two long-time industry veterans, Gary Troxel, CEO, and Shil Kothari, president, formed GHA five years ago to search for unique, novel and proprietary ingredients. GHA is the first U.S.-based nutraceutical company dedicated to developing and producing natural ingredients and active compounds from West Africa. One such ingredient is Irvingia gabonensis. GHA has developed and patented the Irvingia gabonensis seed extract, which is supported by published clinical university studies and has been trademarked as IGOB131™. In addition to owning the rights to U.S. Patent No. 7,537,790, GHA holds several patent pending applications covering its innovations with Irvingia gabonensis.
Dr. Julius Oben, Ph.D., head of the Department of Biochemistry, University of Yaoundé I, Yaoundé, Cameroon, discovered the potential weight loss properties and other health related benefits of Irvingia gabonensis. According to Dr. Oben, certain Irvingia gabonensis extracts had hypolipidemic, anti α-amylase, anti-inflammatory and gene expression activity, thus reducing the amount of ingested starches that would be absorbed as sugar. Dr. Oben’s findings are backed by published clinical university studies.
In a randomized, double-blind, placebo controlled investigation conducted at the University of Yaoundé I, Oben found Irvingia gabonensis was shown to significantly reduce body weight and improve metabolic parameters in overweight humans.
Dr. Oben conducted two studies, the results of which are summarized at (www.lipidworld.com/content/8/1/7 and www.lipidworld.com/content/7/1/44). Both studies demonstrate that IGOB131™ significantly reduces body fat and improves metabolic parameters in overweight humans and also may play an important role in the control of adipogenesis and have further implications in in-vivo anti-obesity effects by targeting the PPAR gamma gene, a known contributing factor to obesity in humans. IGOB131™ unlocks leptin resistance via lowering C-reactive protein levels and helping restore the weight control effects of leptin on appetite and metabolism.
“After filing the early patents, Dr. Oben approached GHA with his research,” said Kothari. “We thoroughly reviewed his science and clinical research that supports product claims,” noted Kothari.
“We commissioned a larger study to determine if there was a statistical significance of previous work and measured other parameters associated with weight loss factors,” said Troxel. “We found IGOB131™ was an effective agent to aid in healthy body recomposition by addressing multiple pathways and mechanisms that improve overall health,” Troxel added.
IGOB131™ is the only clinically researched and patented Irvingia gabonensis seed extract and sold exclusively by GHA.
Gateway Health Alliances, Inc. is a privately-owned company founded in 2005 with a focus on research, manufacturing and distribution of unique, clinically researched and patent protected ingredients. GHA is primarily dedicated to the identification, development and production of active compounds sourced from West Africa. The company success is based on its research, including the screening of novel plants for their clinical benefits and the identification of new active principles.
Gateway Health Alliances is also involved in the development of extraction and purification systems providing safe and efficacious ingredients for a select group of key partners in targeted markets and various distribution channels around the world.
For more information contact Gary Troxel at 707.208.8489 or by email at [email protected].